Behind a weaker first half
Judges Scientific (LSE:JDG), the AIM-quoted group that buys and runs specialist scientific instrument businesses, reported a 21% fall in Revenue for the first half of 2026. Its chair called it "a very poor first half performance". This article examines the reasons the company gave, in particular the effect of US science funding and procurement delays in China, and what it said about the rest of the year.
The business
Judges Scientific owns 25 businesses acquired since 2005, mostly based in the UK, which make instruments sold worldwide to scientific institutions, manufacturers and regulators. It reports two segments, Materials Sciences and Vacuum. One of its businesses, Geotek, provides core-scanning equipment and services, including large coring expeditions that can make its revenue lumpy. Tim Prestidge is chief executive and David Cicurel is chair.
The interim results
On 23 September 2026, the company reported revenue of £55.7m for the six months to 30 June 2026, down from £70.2m. It said the absence of a Geotek coring expedition accounted for about eight percentage points of the decline, while headwinds from US science funding, offshore wind delays and Chinese procurement disruption accounted for around 13 points. Eight businesses grew in the period.
Adjusted operating profit fell 66% to £4.8m from £14.3m. The statutory result was a loss before tax of £1.7m, after £4.9m of adjusting items, mainly Amortisation of acquired intangibles. Adjusted Basic Earnings Per Share fell to 39.0p from 141.4p. Materials Sciences revenue dropped to £25.1m from £35.7m, and Vacuum revenue to £30.6m from £34.5m. Despite this, the board raised the Interim Dividend 10% to 36.0p from 32.7p. Cash generated from operations was £4.3m, against £12.3m a year earlier.
US funding and China
The company said US science funding created "continued uncertainties", noting that funds had "not flowed normally" even though Congress rejected proposed budget cuts, and that the administration had signalled a desire to reduce the federal science budget in 2027. In China, delays in finalising new R&D tax exemption processes for government-funded scientific equipment purchases weighed heavily, with order intake in China and Hong Kong down 47%. The company said it had seen "early signs" of resolution. It added that the conflict in Iran had resulted in only a very small value of lost orders.
Group order intake fell 12% in the half, but the order book was 17.3 weeks, almost unchanged from 17.4 weeks a year earlier. The company said second-half order intake had improved significantly, leaving year-to-date intake only 1% behind. It also said a Geotek expedition customer's next expedition "will be scheduled no earlier than 2028". The board maintained guidance of "Adjusted earnings per share in line with current market expectations."
Balance sheet, board and risks
Adjusted net Debt rose to £45.3m from £42.6m at the end of 2025, and gearing increased to 2.1 times from 1.5 times. Banking facilities were extended by two years to 1 July 2030. In a separate announcement on 23 September 2026, the company said chief financial officer Brad Ormsby will step down with effect from 23 September 2027 after more than a decade with the group.
The main risks are continued weakness in US academic funding, slower-than-expected resolution in China and the absence of Geotek expedition revenue until 2028. Meeting full-year expectations depends on what the company called "greater-than-usual final quarter phasing", which leaves less room for delays. Higher gearing also reduces financial flexibility for acquisitions.
Conclusion
Judges Scientific attributed its lower interim revenue to the absence of a Geotek expedition and to disruption from US science funding, offshore wind delays and Chinese procurement processes. The company held its earnings guidance and raised its dividend, but its second half must be considerably better for that guidance to be met.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...